Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Safe Superintelligence is an AI research lab that is trying to build a superintelligent AI system while making safety its top priority, and it currently makes no product or revenue.
Safe Superintelligence is a research lab, not a normal business. It has no product to sell, no customers, and no revenue. What it has is a single, almost absurdly ambitious goal: build an AI that is far smarter than humans — a "superintelligence" — and make sure it is safe before anything else. That is the whole pitch, and it is why the company exists.
The lab was founded in 2024 by Ilya Sutskever, the former chief scientist of OpenAI, along with Daniel Gross and Daniel Levy. Sutskever is one of the most respected researchers in the field, and his departure from OpenAI after a board fight made headlines around the world. He then started this company with a deliberately strange structure: one team, one focus, one product. No side projects, no distractions, no shipping chatbots to chase users. The bet is that a small group of brilliant researchers, free from commercial pressure, can make progress on the hardest problem in the field. So how does a company with no revenue survive? It raises money from investors who are willing to wait a very long time. In 2024 it raised about $1 billion, and in 2025 it raised another $2 billion at a valuation of roughly $32 billion, according to reports. Backers include venture firms like Sequoia and Andreessen Horowitz, plus Alphabet's Google and Nvidia. Those investors are not buying current cash flow. They are buying a shot at being early to something that could change everything — and they accept that the payoff, if it ever comes, is years away.
The obvious comparison is OpenAI-backed OpenAI, Anthropic-backed Anthropic, and Google DeepMind-owned DeepMind. All of them are racing toward powerful AI too, but they are also selling products today to fund the work. Safe Superintelligence is making the opposite trade: stay small, stay private, and refuse to let commercial deadlines shape the research. Whether that purity is a strength or a weakness is the real question. The company is placing a huge, patient bet that safety and superintelligence can be solved by a focused team before the rest of the industry stumbles into the problem at full speed.
Saved answer · last researched 4 Nov 2026